{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:09:30Z","timestamp":1790388570949,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA121973"],"award-info":[{"award-number":["P50CA121973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["M01-RR-000056"],"award-info":[{"award-number":["M01-RR-000056"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["CTSA"],"award-info":[{"award-number":["CTSA"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00262-017-2090-z","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T05:18:09Z","timestamp":1512364689000},"page":"423-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1007","volume":"67","author":[{"given":"Larisa J.","family":"Geskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonyou","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schowalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Louis D.","family":"Falo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"issue":"14","key":"2090_CR1","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","volume":"19","author":"E Guenova","year":"2013","unstructured":"Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA (2013) Th2 cytokines from malignant cells suppress Th1 responses and enforce a global Th2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19(14):3755\u20133763. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3488","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2090_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1067\/mjd.2001.116345","volume":"45","author":"EK Yoo","year":"2001","unstructured":"Yoo EK, Cassin M, Lessin SR, Rook AH (2001) Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol 45(2):208\u2013216. \n                    https:\/\/doi.org\/10.1067\/mjd.2001.116345","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2090_CR3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1172\/JCI24826","volume":"115","author":"EJ Kim","year":"2005","unstructured":"Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Investig 115(4):798\u2013812. \n                    https:\/\/doi.org\/10.1172\/JCI24826","journal-title":"J Clin Investig"},{"issue":"4","key":"2090_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2340\/00015555-1496","volume":"93","author":"E Hodak","year":"2013","unstructured":"Hodak E, Lessin S, Friedland R, Freud T, David M, Pavlovsky L, Shapiro J, Cohen AD (2013) New insights into associated co-morbidities in patients with cutaneous T-cell lymphoma (mycosis fungoides). Acta Derm Venereol 93(4):451\u2013455. \n                    https:\/\/doi.org\/10.2340\/00015555-1496","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"2090_CR5","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1172\/JCI78089","volume":"125","author":"JA Bluestone","year":"2015","unstructured":"Bluestone JA, Bour-Jordan H, Cheng M, Anderson M (2015) T cells in the control of organ-specific autoimmunity. J Clin Investig 125(6):2250\u20132260. \n                    https:\/\/doi.org\/10.1172\/JCI78089","journal-title":"J Clin Investig"},{"issue":"2","key":"2090_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/0192623311430693","volume":"40","author":"RA Peterson","year":"2012","unstructured":"Peterson RA (2012) Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 40(2):186\u2013204. \n                    https:\/\/doi.org\/10.1177\/0192623311430693","journal-title":"Toxicol Pathol"},{"issue":"4","key":"2090_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/eji.201444999","volume":"45","author":"W Chen","year":"2015","unstructured":"Chen W, Konkel JE (2015) Development of thymic Foxp3(+) regulatory T cells: TGF-beta matters. Eur J Immunol 45(4):958\u2013965. \n                    https:\/\/doi.org\/10.1002\/eji.201444999","journal-title":"Eur J Immunol"},{"issue":"3","key":"2090_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1172\/JCI57175","volume":"123","author":"A Chaudhry","year":"2013","unstructured":"Chaudhry A, Rudensky AY (2013) Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Investig 123(3):939\u2013944. \n                    https:\/\/doi.org\/10.1172\/JCI57175","journal-title":"J Clin Investig"},{"key":"2090_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0065-2776(10)05004-2","volume":"105","author":"K Fujio","year":"2010","unstructured":"Fujio K, Okamura T, Yamamoto K (2010) The family of IL-10-secreting CD4+ T cells. Adv Immunol 105:99\u2013130. \n                    https:\/\/doi.org\/10.1016\/S0065-2776(10)05004-2","journal-title":"Adv Immunol"},{"issue":"1","key":"2090_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/sj.jid.5700004","volume":"126","author":"S Beissert","year":"2006","unstructured":"Beissert S, Schwarz A, Schwarz T (2006) Regulatory T cells. J Investig Dermatol 126(1):15\u201324. \n                    https:\/\/doi.org\/10.1038\/sj.jid.5700004","journal-title":"J Investig Dermatol"},{"issue":"2","key":"2090_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00262-011-1171-7","volume":"61","author":"TL Whiteside","year":"2012","unstructured":"Whiteside TL (2012) Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 61(2):283\u2013288. \n                    https:\/\/doi.org\/10.1007\/s00262-011-1171-7","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2090_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-2141.2011.08678.x","volume":"153","author":"T Tadmor","year":"2011","unstructured":"Tadmor T, Attias D, Polliack A (2011) Myeloid-derived suppressor cells\u2014their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 153(5):557\u2013567. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08678.x","journal-title":"Br J Haematol"},{"issue":"9","key":"2090_CR13","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Investig 125(9):3356\u20133364. \n                    https:\/\/doi.org\/10.1172\/JCI80005","journal-title":"J Clin Investig"},{"issue":"5","key":"2090_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","volume":"102","author":"H Sun","year":"2015","unstructured":"Sun H, Li Y, Zhang ZF, Ju Y, Li L, Zhang BC, Liu B (2015) Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol 102(5):579\u2013586. \n                    https:\/\/doi.org\/10.1007\/s12185-015-1865-2","journal-title":"Int J Hematol"},{"issue":"5","key":"2090_CR15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","volume":"124","author":"R Jitschin","year":"2014","unstructured":"Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, Krause SW, Oefner PJ, Le Blanc K, Mackensen A, Mougiakakos D (2014) CLL-cells induce IDOhi CD14+ HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote. Blood 124(5):750\u2013760. \n                    https:\/\/doi.org\/10.1182\/blood-2013-12-546416","journal-title":"Blood"},{"issue":"2","key":"2090_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.imlet.2015.10.001","volume":"168","author":"A Florcken","year":"2015","unstructured":"Florcken A, Takvorian A, Singh A, Gerhardt A, Ostendorf BN, Dorken B, Pezzutto A, Westermann J (2015) Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. Immunol Lett 168(2):260\u2013267. \n                    https:\/\/doi.org\/10.1016\/j.imlet.2015.10.001","journal-title":"Immunol Lett"},{"issue":"10","key":"2090_CR17","doi-asserted-by":"publisher","first-page":"7987","DOI":"10.1007\/s13277-015-3426-y","volume":"36","author":"H Huang","year":"2015","unstructured":"Huang H, Zhang G, Li G, Ma H, Zhang X (2015) Circulating CD14(+)HLA-DR(\u2212\/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. Tumour Biol 36(10):7987\u20137996. \n                    https:\/\/doi.org\/10.1007\/s13277-015-3426-y","journal-title":"Tumour Biol"},{"issue":"3","key":"2090_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/leu.2011.237","volume":"26","author":"T Krejsgaard","year":"2012","unstructured":"Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A (2012) Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 26(3):424\u2013432. \n                    https:\/\/doi.org\/10.1038\/leu.2011.237","journal-title":"Leukemia"},{"issue":"4","key":"2090_CR19","first-page":"553","volume":"18","author":"QA Zhang","year":"2014","unstructured":"Zhang QA, Chen ZQ, Chen MH, Xu ZD (2014) The number of regular T cells and immature dendritic cells involved in mycosis fungoides is linked to the tumor stage. Eur Rev Med Pharmacol Sci 18(4):553\u2013558","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"13","key":"2090_CR20","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.7314\/APJCP.2015.16.13.5359","volume":"16","author":"MM Shareef","year":"2015","unstructured":"Shareef MM, Elgarhy LH, Wasfy Rel S (2015) Expression of granulysin and Foxp3 in cutaneous T cell lymphoma and Sezary syndrome. Asian Pac J Cancer Prev 16(13):5359\u20135364","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"2090_CR21","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1038\/sj.jid.5700371","volume":"126","author":"MM Tiemessen","year":"2006","unstructured":"Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S (2006) Lack of suppressive CD4+ CD25+ FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Investig Dermatol 126(10):2217\u20132223. \n                    https:\/\/doi.org\/10.1038\/sj.jid.5700371","journal-title":"J Investig Dermatol"},{"issue":"4","key":"2090_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/phpp.12175","volume":"31","author":"LH Shiue","year":"2015","unstructured":"Shiue LH, Couturier J, Lewis DE, Wei C, Ni X, Duiv M (2015) The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(\u2212) T cells in patients with leukemic cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 31(4):184\u2013194. \n                    https:\/\/doi.org\/10.1111\/phpp.12175","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"3","key":"2090_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000094678","volume":"116","author":"S Barath","year":"2006","unstructured":"Barath S, Aleksza M, Keresztes K, Toth J, Sipka S, Szegedi G, Illes A (2006) Immunoregulatory T cells in the peripheral blood of patients with Hodgkin\u2019s lymphoma. Acta Haematol 116(3):181\u2013185. \n                    https:\/\/doi.org\/10.1159\/000094678","journal-title":"Acta Haematol"},{"issue":"12","key":"2090_CR24","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1038\/jid.2009.175","volume":"129","author":"JB Heid","year":"2009","unstructured":"Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E, Klemke CD (2009) FOXP3+ CD25\u2212 tumor cells with regulatory function in Sezary syndrome. J Investig Dermatol 129(12):2875\u20132885. \n                    https:\/\/doi.org\/10.1038\/jid.2009.175","journal-title":"J Investig Dermatol"},{"issue":"3","key":"2090_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cei.12073","volume":"172","author":"T Hanafusa","year":"2013","unstructured":"Hanafusa T, Matsui S, Murota H, Tani M, Iqawa K, Katayama I (2013) Increased frequency of skin-infiltrating FoxP3+ regulatory T cells as a diagnostic indicator of severe atopic dermatitis from cutaneous T cell lymphoma. Clin Exp Immunol 172(3):507\u2013512. \n                    https:\/\/doi.org\/10.1111\/cei.12073","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2090_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1084\/jem.20041982","volume":"201","author":"R Setoguchi","year":"2005","unstructured":"Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201(5):723\u2013735. \n                    https:\/\/doi.org\/10.1084\/jem.20041982","journal-title":"J Exp Med"},{"issue":"7","key":"2090_CR27","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1084\/jem.20060772","volume":"203","author":"W Liu","year":"2006","unstructured":"Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, de St Fazekas, Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203(7):1701\u20131711. \n                    https:\/\/doi.org\/10.1084\/jem.20060772","journal-title":"J Exp Med"},{"issue":"6","key":"2090_CR28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1080\/10428190802064917","volume":"49","author":"E Capriotti","year":"2008","unstructured":"Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW, Hess AD (2008) Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 49(6):1190\u20131201. \n                    https:\/\/doi.org\/10.1080\/10428190802064917","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2090_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaad.2010.01.013","volume":"69","author":"DA Wada","year":"2013","unstructured":"Wada DA, Pittelkow MR, Comfere NI, Gibson LE, Ansell SM, Wilcox RA (2013) CD4(+)CD25(+)FOXP3(+) malignant T cells in Sezary syndrome are not necessarily functional regulatory T cells. J Am Acad Dermatol 69(3):485\u2013489. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2010.01.013","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2090_CR30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"E Olsen","year":"2001","unstructured":"Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19(2):376\u2013388. \n                    https:\/\/doi.org\/10.1200\/JCO.2001.19.2.376","journal-title":"J Clin Oncol"},{"issue":"4","key":"2090_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.clml.2013.02.020","volume":"13","author":"M Duvic","year":"2013","unstructured":"Duvic M, Geskin L, Prince HM (2013) Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk 13(4):377\u2013384. \n                    https:\/\/doi.org\/10.1016\/j.clml.2013.02.020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2090_CR32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4049\/jimmunol.174.2.636","volume":"174","author":"P Sinha","year":"2005","unstructured":"Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174(2):636\u2013645","journal-title":"J Immunol"},{"issue":"7","key":"2090_CR33","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1078-0432.CCR-10-2672","volume":"17","author":"C Zoglmeier","year":"2011","unstructured":"Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C (2011) CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 17(7):1765\u20131775. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2672","journal-title":"Clin Cancer Res"},{"key":"2090_CR34","first-page":"2017","volume-title":"Dermatology","author":"R Willemze","year":"2012","unstructured":"Willemze R (2012) Cutaneous T-cell lymphoma. In: Bolognia JL, Jorizzo JL, Schaffer JV (eds) Dermatology, 3rd edn. Elsevier, London, pp 2017\u20132036","edition":"3"},{"issue":"4","key":"2090_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","volume":"16","author":"EA Olsen","year":"2003","unstructured":"Olsen EA (2003) Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 16(4):311\u2013321","journal-title":"Dermatol Ther"},{"issue":"7\u20138","key":"2090_CR36","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.intimp.2009.03.015","volume":"9","author":"HK Le","year":"2009","unstructured":"Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD (2009) Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 9(7\u20138):900\u2013909. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2009.03.015","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2090_CR37","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1002\/eji.200939453","volume":"39","author":"CH Poehlein","year":"2009","unstructured":"Poehlein CH, Haley DP, Walker EB, Fox BA (2009) Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol 39(11):3121\u20133133. \n                    https:\/\/doi.org\/10.1002\/eji.200939453","journal-title":"Eur J Immunol"},{"issue":"12","key":"2090_CR38","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/ng.3442","volume":"47","author":"AC da Silva Almeida","year":"2015","unstructured":"da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, Vermeer MH, Rabadan R, Ferrando A, Palomero T (2015) The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet 47(12):1465\u20131470. \n                    https:\/\/doi.org\/10.1038\/ng.3442","journal-title":"Nat Genet"},{"issue":"1","key":"2090_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1182\/blood-2008-04-153031","volume":"113","author":"R van Doorn","year":"2009","unstructured":"van Doorn R, van Kester MS, Dijkman R, Vermeer MH, Mulder AA, Szuhai K, Knijnenburg J, Boer JM, Willemze R, Tensen CP (2009) Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 113(1):127\u2013136. \n                    https:\/\/doi.org\/10.1182\/blood-2008-04-153031","journal-title":"Blood"},{"issue":"4","key":"2090_CR40","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","volume":"105","author":"CL Berger","year":"2005","unstructured":"Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL (2005) Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 105(4):1640\u20131647. \n                    https:\/\/doi.org\/10.1182\/blood-2004-06-2181","journal-title":"Blood"},{"issue":"13","key":"2090_CR41","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1182\/blood-2012-09-456988","volume":"122","author":"AS Baur","year":"2013","unstructured":"Baur AS, Lutz MB, Schierer S, Beltrame L, Theiner G, Zinser E, Ostalecki C, Heidkamp G, Haendle I, Erdmann M, Wiesinger M, Leisgang W, Gross S, Pommer AJ, Kampgen E, Dudziak D, Steinkasserer A, Cavalieri D, Schuler-Thurner B, Schuler G (2013) Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. Blood 122(13):2185\u20132194. \n                    https:\/\/doi.org\/10.1182\/blood-2012-09-456988","journal-title":"Blood"},{"issue":"3","key":"2090_CR42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.chom.2009.06.009","volume":"6","author":"C Muratori","year":"2009","unstructured":"Muratori C, Cavallin LE, Kratzel K, Tinari A, De Milito A, Fais S, D\u2019Aloja P, Federico M, Vullo V, Fomina A, Mesri EA, Superti F, Baur AS (2009) Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 6(3):218\u2013230. \n                    https:\/\/doi.org\/10.1016\/j.chom.2009.06.009","journal-title":"Cell Host Microbe"},{"issue":"5","key":"2090_CR43","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.vaccine.2008.11.042","volume":"27","author":"CM Chuang","year":"2009","unstructured":"Chuang CM, Hoory T, Monie A, Wu A, Wang MC, Hung CF (2009) Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine 27(5):684\u2013689. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2008.11.042","journal-title":"Vaccine"},{"issue":"11","key":"2090_CR44","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/cup.12217","volume":"40","author":"E Castano","year":"2013","unstructured":"Castano E, Glick S, Wolgast L, Naeem R, Sunkara J, Elston D, Jacobson M (2013) Hypopigmented mycosis fungoides in childhood and adolescence: a long-term retrospective study. J Cutan Pathol 40(11):924\u2013934. \n                    https:\/\/doi.org\/10.1111\/cup.12217","journal-title":"J Cutan Pathol"},{"issue":"12","key":"2090_CR45","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1002\/ijc.22617","volume":"120","author":"K Mahnke","year":"2007","unstructured":"Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, Johnson TS, Storn V, Schallenberg S, Enk AH (2007) Depletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120(12):2723\u20132733. \n                    https:\/\/doi.org\/10.1002\/ijc.22617","journal-title":"Int J Cancer"},{"issue":"3","key":"2090_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162\u2013174. \n                    https:\/\/doi.org\/10.1038\/nri2506","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2090_CR47","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69(4):1553\u20131560. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1921","journal-title":"Cancer Res"},{"issue":"12","key":"2090_CR48","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.4049\/jimmunol.1400404","volume":"192","author":"JM Weiss","year":"2014","unstructured":"Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH (2014) Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo fas-dependent cell death during IL-2\/alphaCD40 therapy. J Immunol 192(12):5821\u20135829. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1400404","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2090-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T10:37:51Z","timestamp":1589625471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,4]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2090-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,4]]},"assertion":[{"value":"30 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was supported by Research Center Grants for Specialized Programs of Research of Excellence (P50CA121973) of National Institute of Health, Clinical and Translational Science and M01 Award of National Center for Research Resources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}